Literature DB >> 17204048

The correlation of CTG repeat length with material and social deprivation in myotonic dystrophy.

L Laberge1, S Veillette, J Mathieu, J Auclair, M Perron.   

Abstract

Socioeconomic deprivation has long been recognized as a prominent feature of myotonic dystrophy type 1 (DM1), but studies performed before the discovery of the mutation causing DM1 may have suffered an ascertainment bias towards the more severe forms of the disease. We have sought to clarify the relationship between CTG repeats, muscular impairment, and socioeconomic characteristics of 200 patients with DM1. Patients with DM1 reported lower educational attainment, lower employment rate, lower family income, and higher reliance on social assistance than the reference population. Logistic regression showed, on one hand, that CTG repeats and marital status were significant predictors of social assistance recipiency and, on the other hand, that CTG repeats and gender were significant predictors of low social support from family, after adjustment for age, gender, degree of muscular impairment, CTG repeats, educational level, and marital status. For example, each additional 100 CTG repeats was found to increase the odds of relying on social assistance by about 35% and having low social support by about 22%. The chances of experiencing socioeconomic deprivation are loaded heavily against patients with DM1. The relationship between increased CTG repeat length and higher risk of material and social deprivation must be acknowledged in the clinical management of DM1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17204048     DOI: 10.1111/j.1399-0004.2007.00732.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

1.  Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases.

Authors:  Jean-Pierre Bouchard; Louise Cossette; Guillaume Bassez; Jack Puymirat
Journal:  J Neurol       Date:  2014-11-08       Impact factor: 4.849

2.  A 9-year follow-up study of quantitative muscle strength changes in myotonic dystrophy type 1.

Authors:  Cynthia Gagnon; Émilie Petitclerc; Marie Kierkegaard; Jean Mathieu; Élise Duchesne; Luc J Hébert
Journal:  J Neurol       Date:  2018-05-21       Impact factor: 4.849

3.  Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).

Authors:  Chad Heatwole; Rita Bode; Nicholas Johnson; Christine Quinn; William Martens; Michael P McDermott; Nan Rothrock; Charles Thornton; Barbara Vickrey; David Victorson; Richard Moxley
Journal:  Neurology       Date:  2012-07-11       Impact factor: 9.910

4.  Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with myotonic dystrophy.

Authors:  Robert Breton; Jean Mathieu
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

5.  Predicting daytime sleepiness and fatigue: a 9-year prospective study in myotonic dystrophy type 1.

Authors:  Luc Laberge; Benjamin Gallais; Julie Auclair; Yves Dauvilliers; Jean Mathieu; Cynthia Gagnon
Journal:  J Neurol       Date:  2019-10-31       Impact factor: 4.849

6.  Comparisons of intellectual capacities between mild and classic adult-onset phenotypes of myotonic dystrophy type 1 (DM1).

Authors:  Stéphane Jean; Louis Richer; Luc Laberge; Jean Mathieu
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

7.  Synaptic protein dysregulation in myotonic dystrophy type 1: Disease neuropathogenesis beyond missplicing.

Authors:  Oscar Hernández-Hernández; Géraldine Sicot; Diana M Dinca; Aline Huguet; Annie Nicole; Luc Buée; Arnold Munnich; Nicolas Sergeant; Geneviève Gourdon; Mário Gomes-Pereira
Journal:  Rare Dis       Date:  2013-06-26

8.  Social cognition in myotonic dystrophy type 1: Specific or secondary impairment?

Authors:  Garazi Labayru; Irati Arenzana; Jone Aliri; Miren Zulaica; Adolfo López de Munain; Andone Sistiaga A
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.